ArticleBlood advances2023

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.

Kitsada Wudhikarn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.